[1]史展 孙雪荣 田颖 刘兴鹏.心房颤动患者口服抗凝药物依从性的研究进展[J].心血管病学进展,2020,(1):18-22.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.006]
　SHI Zhan,SUN Xuerong,TIAN Ying,et al.Drug Adherence to Oral Anticoagulant Therapy among Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(1):18-22.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.006]
点击复制

心房颤动患者口服抗凝药物依从性的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年1期
页码:
18-22
栏目:
综述
出版日期:
2020-02-04

文章信息/Info

Title:
Drug Adherence to Oral Anticoagulant Therapy among Patients with Atrial Fibrillation
作者:
史展1 孙雪荣 1 田颖1; 2 刘兴鹏1; 2
(1.首都医科大学第三临床医学院,北京100009;2.首都医科大学附属北京朝阳医院心脏中心,北京100020)
Author(s):
SHI Zhan 1; SUN Xuerong1; TIAN Ying1; 2; LIU Xingpeng1; 2
(1.The Third Clinical Medical SchoolCapital Medical UniversityBeijing 100009China2.Heart CenterBeijing Chaoyang HospitalCapital Medical UniversityBeijing 100023China)
关键词:
口服抗凝药物; 药物依从性; 心房颤动
Keywords:
Oral anticoagulation;  Drug adherence ;  Atrial fibrillation
DOI:
10.16806/j.cnki.issn.1004-3934.2020.01.006
摘要:
心房颤动是临床上最常见的心律失常，80岁以上人群心房颤动的患病率约为10％。心房颤动可使卒中风险增加5～17倍，口服抗凝剂可有效预防心房颤动相关的血栓栓塞性脑卒中发生。所以，提高心房颤动患者口服抗凝药物治疗的依从性至关重要。现针对药物依从性的影响因素、评估方法、依从性现状和改善策略进行综述。
Abstract:
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia a nd the AF prevalence of people over 80 years of age is about 10%.Patients with AF have 5 to 17 times elevated risk of ischemic stroke ,which can be effectiv ely prevented by oral anticoagulation. Thus,it is essential to improve the drug adherence to oral anticoagulation therapy in patients with AF .This paper reviews the influencing factors, evaluation methods, status quo and improvement strategies of drug adherence.

参考文献/References:

[1] Camm AJ,Lip GY,de Caterina R,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation:an update of the 2010 ESC Guidelines for the management of atrial fibrillation—developed with the special contribution of the European Heart Rhythm Association[J]. Europace ,2012,14(10):1385-1413.

[2] Kirchhof P,Benussi S,Kotecha D,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Kardiol Pol,2016,74(12):1359-1469.

[3]Smet L,Heggermont WA,Goossens E,et al. Adherence,knowledge and perception about oral anticoagulants in patients with atrial fibrillation at high risk for thromboembolic events after radiofrequency ablation[J]. J Adv Nurs ,2018,74(11):2577-2587.

[4] Casciano J P,Dotiwala ZJ,Martin BC,et al. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation:a commercial insurer perspective[J]. J Manag Care Pharm,2013,19(4):302-316.

[5] Yao X,Abraham NS,Alexander GC,et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation[J]. J Am Heart Assoc,2016,5(2):e003074.

[6] Vrijens B,Heidbuchel H. Non-vitamin K antagonist oral anticoagulants:considerations on once- vs. twice-daily regimens and their potential impact on medication adherence[J]. Europace,2015,17(4):514-523.

[7] Ewen S,Rettigewen V,Mahfoud F,et al. Drug adherence in patients taking oral anticoagulation therapy[J]. Clin Res Cardiol,2014,103(3):173-182.

[8] 陈静,李兴德. 冠心病患者服药依从性的研究进展[J]. 心血管病学进展,2015,36(6):728-731.

[9] Fang MC,Go AS,Chang Y,et al. Warfarin discontinuation after starting warfarin for atrial fibrillation[J]. Circ Cardiovasc Qual Outcomes,2010,3(6):624-631.

[10] Beyer-Westendorf J ,Ehlken B,Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation[J]. Europace,2016,18(8):1150-1157.

[11] Devereaux PJ,Anderson DR,Gardner MJ,et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation:observational study[J]. BMJ,2001,323(7323):1218-1222.

[12] Manzoor BS ,Lee TA,Sharp LK,et al. Real-world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation[J]. Pharmacotherapy,2017,37(10):1221-1230.

[13] Onder G,Bonassi S,Abbatecola AM,et al. High prevalence of poor quality drug prescribing in older individuals:a nationwide report from the Italian Medicines Agency (AIFA)[J]. J Gerontol A Biol Sci Med Sci,2014,69(4):430-437.

[14] Proietti M,Raparelli V,Olshansky B,et al. Polypharmacy and major adverse events in atrial fibrillation:observations from the AFFIRM trial[J]. Clin Res Cardiol,2016,105(5):412-420.

[15] Giardini A,Martin MT,Cahir C,et al. Toward appropriate criteria in medication adherence assessment in older persons:position paper[J]. Aging Clin Exp Res,2016,28(3):371-381.

[16] Obamiro KO ,Chalmers L,Bereznicki LR. A summary of the literature evaluating adherence and persistence with oral anticoagulants in atrial fibrillation[J]. Am J Cardiovasc Drugs,2016,16(5):349-363.

[17] Garkina SV,Vavilova TV,Lebedev DS,et al. Compliance and adherence to oral anticoagulation therapy in elderly patients with atrial fibrillation in the era of direct oral anticoagulants[J]. J Geriatr Cardiol,2016,13(9):807-810.

[18] Laliberté F,Nelson WW,Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients[J]. Adv Ther,2012,29(8):675-690.

[19] Scirica BM ,Bansilal S,Davoudi F,et al. Safety of ticagrelor in patients with baseline conduction abnormalities:A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis[J]. Am Heart J,2018,202:54-60..

[20] 邹川,吴柏杨,廖晓阳. 高血压服药依从性的研究进展[J]. 心血管病学进展,2013,34(1):131-134.

[21] Awwad O,Akour A,Al-Muhaissen S,et al. The influence of patients’ knowledge on adherence to their chronic medications:a cross-sectional study in Jordan[J]. Int J Clin Pharm,2015,37(3):504-510.

[22] Arnet I ,Metaxas C,Walter PN,et al. The 8-item Morisky Medication Adherence Scale translated in German and validated against objective and subjective polypharmacy adherence measures in cardiovascular patients[J]. J Eval Clin Pract,2015,21(2):271-277.

[23] Castellucci LA,Shaw J,van der Salm K, et al. Self-reported adherence to anticoagulation and its determinants using the morisky medication adherence scale[J]. Thromb Rese,2015,136(4):727-731.

[24] McRae-Clark AL,Baker NL,Sonne SC,et al. Concordance of direct and indirect measures of medication adherence in a treatment trial for cannabis dependence[J]. J Subst Abuse Treat,2015,57:70-74.

[25] Arnet I,Walter PN,Hersberger KE . Polymedication Electronic Monitoring System (POEMS)—a new technology for measuring adherence[J].Front Pharmacol,2013,4:26.

[26] Chan AH,Reddel HK,Apter A, et al. Adherence monitoring and e-health:how clinicians and researchers can use technology to promote inhaler adherence for asthma[J]. J Allergy Clin Immunol Pract,2013,1(5):446-454.

[27] Lugaresi A. RebiSmartTM(version 1.5) device for multiple sclerosis treatment delivery and adherence[J]. Expert Opin Drug Deliv,2013,10(2):273-283.

[28] Desteghe L,Vijgen J,Koopman P,et al.Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation[J].Eur Heart J,2018,39(16):1394-1403.

[29] Schulman S,Shortt B,Robinson M,et al. Adherence to anticoagulant treatment with dabigatran in a real-world setting[J]. J Thromb Haemost,2013,11(7):1295-1299.

[30] Tsai K,PharmD,Erickson SC,et al. Adherence,persistence,and switching patterns of dabigatran etexilate[J]. Am J Manag Care,2013,19(9):325-332.

[31] Hecker J,Marten S,Keller L,et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation[J]. Thromb Haemost,2016,115(5):939-949.

[32] Nelson WW,Song X,Coleman C I,et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation[J]. Curr Med Res Opin,2014,30(12):2461-2469.

[33] Alberts MJ,Peacock WF,Fields LE,et al. Association between once-and twice-daily direct oral anticoagulant adherence in nonvalvular atrial fibrillation patients and rates of ischemic stroke[J]. Int J Cardiol,2016,215:11-13.

[34] Heidbuchel H, Verhamme P, Alings M ,et al.European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation[J]. Europace,2013,15(5):625-651.

[35] Hendriks JM,de Wit R,Crijns HJ,et al. Nurse-led care vs. usual care for patients with atrial fibrillation:results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation[J]. Eur Heart J,2012,33(21):2692-2699.

[36] Timmers L ,Boons CC,Verbrugghe M,et al. Supporting adherence to oral anticancer agents:clinical practice and clues to improve care provided by physicians,nurse practitioners,nurses and pharmacists[J]. BMC Cancer,2017,17(1):122.

[37] Wu JY,Leung WY,Chang S,et al. Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy:randomised controlled trial[J]. BMJ,2006,333(7567):522-525.

[38] Morawski K,Ghazinouri R,Krumme A,et al. Association of a smartphone application with medication adherence and blood pressure control:the MedISAFE-BP randomized clinical trial[J]. JAMA Intern Med,2018,178(6):802-809.

相似文献/References:

[1]杨晴 梁岩.非维生素K拮抗剂口服抗凝药物治疗心室附壁血栓形成的探究[J].心血管病学进展,2021,(3):198.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.002]
　YANG Qing,LIANG Yan.Investigation of Non-vitamin K Antagonist Oral Anticoagulants for Treatment of Ventricular Thrombosis[J].Advances in Cardiovascular Diseases,2021,(1):198.[doi:10.16806/j.cnki.issn.1004-3934.2021.03.002]
[2]孙瑶 杨志明.窦性心律心衰患者脑卒中风险评估的研究进展[J].心血管病学进展,2023,(6):528.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.011]
　SUNYao,YANG Zhiming.Risk of stroke in patients with heart failure and sinus rhythm[J].Advances in Cardiovascular Diseases,2023,(1):528.[doi:10.16806/j.cnki.issn.1004-3934.2023.06.011]

备注/Memo

备注/Memo:
通讯作者：刘兴鹏，E-mail：xpliu71@vip.sina.com
更新日期/Last Update: 2020-03-23